Neuromodulation therapy developer BrainsWay (NSDQ:BWAY) announced that it appointed former Dynatronics CEO Christopher von Jako as president and CEO.

The company’s board of directors said von Jako, who will assume the role in January 2020, will be central to Brainsway’s strategic transition to U.S.-based leadership.

Prior to his role as CEO of Dynatronics, von Jako served as president & CEO of NinePoint Medical and held the same positions at NeuroTherm before that. He also worked in senior roles at Integra LifeSciences, Covidien, Medtronic and Radionics. While serving in his new role, von Jako will remain an independent director on the boards of NinePoint and nView Medical.

Dr. David Zacut, BrainsWay’s co-founder, board chair and interim CEO, described von Jako as a “science-driven senior executive with over 25 years of experience managing businesses and leading global medical technology companies.”

“Most importantly, he has significant expertise in developing and commercializing minimally-invasive medical technologies aimed at improving patient experiences and outcomes,” Zacut said.

“I am incredibly honored and grateful to the board for the opportunity to lead this exceptional organization,” added von Jako. “BrainsWay has done an excellent job of developing and obtaining regulatory clearances for its innovative deep transcranial magnetic stimulation system (deep TMS) in multiple large indications. Market demand for deep TMS continues to grow, and I look forward to working with the management team and the board to further accelerate BrainsWay’s commercialization and market adoption efforts in the U.S. and around the globe.”